Rare DiseasesOrphan MedicinesThe absence of adequate national strategies for rare diseases (RD), high medicines prices and insufficient experts' knowledge creates to the barriers in therapy, as well as the added factors of inappropriate diagnostics and difficulties in peoples' access to health care. ...
This study characterizes assistance types, disease areas, insurance and income requirements, patient eligibility criteria, and drugs covered by the 6
This study assessed the long-term risk of death in IMD survivors and their need for state-provided financial assistance. What was learned from the study? Real-world evidence in France over a 6-year period found that 12.9% of IMD cases died, with a third of deaths occurring post-discharge....
an antibody-drug conjugate (ADC), with Keytruda(8) (pembrolizumab, a PD-1 inhibitor) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic
The semiconductor company’s FSC program experiences as described below could be helpful for large companies, including high-tech operations, who are considering an internal financial assistance program for their workers who suffer from a WRD, independent of the national compensation program. Firstly, ...
life-changing for the patients and families impacted by this cancer. The average financial compensation for mesothelioma ranges from$1.1 million to $1.4 million.Learn how we can help you access legal compensation, travel grants, veterans benefits, and other forms of mesothelioma financial assistance....
for help. Assistance can range from $5 to thousands of dollars per donation. Often, businesses will agree to hold fundraisers for local residents in need of money for expensive surgeries and medical costs. If your amputation is due to a genetic disease, the Rare Genomics Institute is a ...
Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, announced that it has entered into credit and...Read Story ...
About Merck We are committed to providing leading innovations for today and the future that save and improve lives around the world.Connect with us on social For patients and health care professionals MerckHelps Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for...
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.